MedPath

The Impact of Preoperative Supplementation of Zinc

Not Applicable
Completed
Conditions
Surgery
Nutrition Disorders
Interventions
Dietary Supplement: Zinc
Registration Number
NCT05785013
Lead Sponsor
Cairo University
Brief Summary

1. Pre operative anthropometric assessment including : weight in kg, height/length and BMI

2. Pre operative Zinc supplementation (dose according to the age) for 7 days preoperatively for cases

3. Postoperative data collection

Detailed Description

Postoperative data collection :

* Length of hospital stay

* Complication and sorting of them

* Lab withdrawal of inflammatory markers on 2-3 day postoperatively

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1
Inclusion Criteria
  1. All children patients with Hirschsprung disease admitted for surgical intervention with different ( age , sex )
  2. Type of surgery : transanal pull through
  3. Whose parents or caregivers approve for the participation in the study
Exclusion Criteria
  1. Patients with emergency situations
  2. Whose parents or caregivers will not apply for the participation in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventionalZinc25 children diagnosed with Hirschsprung disease and planned for elective surgery will be supplemented with Zinc 7 days before the operation . Outcomes will be evaluated thorugh measuring the hospital length stay. Other parameters including inflammatory markers as CRP , CRP /albumin ratio and development of postoperative complications will be assesed and compared between cases and controls
Primary Outcome Measures
NameTimeMethod
The effect of preoerative Zinc supplementation on the hospital length stay in children operated for Hirschsprung's diseasezinc supplemenation for one week

Children oprated for elective surgery for Hirschsprung's disease will be supplemented with zinc seven days before surgery and postoperative data as the duration of hospital length stay in hours will be meausred in both the cases and control groups and comapred.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hoda Atef Abdelsattar Ibrahim

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath